No Data
No Data
Morgan Stanley Maintains Immuneering(IMRX.US) With Sell Rating
Immuneering Price Target Maintained With a $13.00/Share by Chardan Capital
Immuneering Is Maintained at Buy by Chardan Capital
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sana Biotechnology (SANA), Immuneering (IMRX) and Johnson & Johnson (JNJ)
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sector Update: Health Care Stocks Rise in Afternoon Trading
No Data